Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made ...

The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide) follows the publication of the results of the phase 3 ARASENS trial in the New England ...

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plan to submit a UK Marketing Authorisation Application (MAA) for Talicia for treatment ...

RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK approval ...

MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that ...

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal ...

Piflufolastat F18 yields high detection rate even at low PSA levels for prostate cancer ...